What is Leerink Partnrs’ Estimate for ACAD FY2025 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Leerink Partnrs boosted their FY2025 earnings estimates for ACADIA Pharmaceuticals in a note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings of $0.64 per share for the year, up from their prior forecast of $0.50. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

ACAD has been the subject of several other reports. Wall Street Zen raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Cowen reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 11th. Royal Bank Of Canada cut their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating on the stock in a report on Thursday. TD Cowen boosted their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, September 11th. Finally, Needham & Company LLC increased their target price on shares of ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.94.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $22.57 on Monday. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $26.65. The stock has a market cap of $3.81 billion, a PE ratio of 16.97, a P/E/G ratio of 7.90 and a beta of 0.80. The stock’s fifty day moving average is $22.62 and its two-hundred day moving average is $22.00.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.28. The business had revenue of $278.63 million for the quarter, compared to analyst estimates of $276.52 million. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The company’s revenue was up 11.3% on a year-over-year basis. During the same period last year, the business earned $0.20 EPS. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 1,600 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total transaction of $41,568.00. Following the completion of the sale, the director directly owned 25,382 shares of the company’s stock, valued at approximately $659,424.36. This trade represents a 5.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mark C. Schneyer sold 3,498 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $23.65, for a total value of $82,727.70. Following the completion of the transaction, the executive vice president owned 43,447 shares in the company, valued at $1,027,521.55. This trade represents a 7.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 27,098 shares of company stock valued at $678,256. 26.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Comerica Bank lifted its holdings in ACADIA Pharmaceuticals by 4,770.1% in the first quarter. Comerica Bank now owns 43,100 shares of the biopharmaceutical company’s stock valued at $716,000 after acquiring an additional 42,215 shares during the period. Rhumbline Advisers increased its holdings in shares of ACADIA Pharmaceuticals by 100.9% in the 1st quarter. Rhumbline Advisers now owns 352,716 shares of the biopharmaceutical company’s stock valued at $5,859,000 after purchasing an additional 177,188 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $247,000. Woodline Partners LP lifted its stake in shares of ACADIA Pharmaceuticals by 1,003.0% in the first quarter. Woodline Partners LP now owns 295,210 shares of the biopharmaceutical company’s stock valued at $4,903,000 after purchasing an additional 268,445 shares during the period. Finally, Voya Investment Management LLC boosted its holdings in ACADIA Pharmaceuticals by 70.3% during the first quarter. Voya Investment Management LLC now owns 61,585 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 25,418 shares in the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.